Biofrontera Inc BFRI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
-
Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
-
Biofrontera Inc. Reports Strong Second Quarter 2026 Financial Results Driven by 33% Revenue Growth
-
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
Trading Information
- Previous Close Price
- $0.87
- Day Range
- $0.85–0.85
- 52-Week Range
- $0.55–1.66
- Bid/Ask
- $0.87 / $0.90
- Shares Outstanding
- 14.85M
- Market Cap
- $12.65M
- Volume/Avg
- 138 / 500,847
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.22
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 94
- Website
- https://www.biofrontera-us.com
Valuation
|
Metric
|
BFRI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.08 |
Price/Sales | 0.22 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BFRI
|
|---|---|
Quick Ratio | 0.98 |
Current Ratio | 1.18 |
Interest Coverage | −12.12 |
Quick Ratio
BFRI
Profitability
|
Metric
|
BFRI
|
|---|---|
Return on Assets (Normalized) | −22.92% |
Return on Equity (Normalized) | −169.71% |
Return on Invested Capital (Normalized) | −51.52% |
Return on Assets
BFRI
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|#%Z#$^z | LOCK|!kn$ | $73B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|<lqSG%Hb | LOCK|#@#G | $49B | |||
| Haleon PLC ADR
HLN
| LOCK|YFskH>@ | LOCK|JT | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|P>r<>>< | LOCK|@^ | $34B | |||
| Viatris Inc
VTRS
| LOCK|>&^##$ | LOCK|%hC | $21B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|$vW | LOCK|<Ks | $12B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|M#l%HB? | LOCK|>Q | $12B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|<@Wv%@ | LOCK|G?z | $6B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|$p!HrH& | LOCK|J^$?k | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|S#c<$V | LOCK|%?y | $2B |
United States